MCID: GST047
MIFTS: 31

Gastrointestinal Neuroendocrine Tumor

Categories: Cancer diseases, Gastrointestinal diseases, Neuronal diseases

Aliases & Classifications for Gastrointestinal Neuroendocrine Tumor

MalaCards integrated aliases for Gastrointestinal Neuroendocrine Tumor:

Name: Gastrointestinal Neuroendocrine Tumor 12 15
Malignant Gastrointestinal Neuroendocrine Tumor 12
Digestive System Neuroendocrine Neoplasm 73
Digestive System Neuroendocrine Tumor 73

Classifications:



External Ids:

Disease Ontology 12 DOID:0050626

Summaries for Gastrointestinal Neuroendocrine Tumor

Disease Ontology : 12 A gastrointestinal system cancer that has material basis in neuroendocrine cells.

MalaCards based summary : Gastrointestinal Neuroendocrine Tumor, also known as malignant gastrointestinal neuroendocrine tumor, is related to neuroendocrine tumor and carcinoid syndrome. An important gene associated with Gastrointestinal Neuroendocrine Tumor is CDKN1A (Cyclin Dependent Kinase Inhibitor 1A), and among its related pathways/superpathways are Neural Stem Cell Differentiation Pathways and Lineage-specific Markers and Hepatitis C and Hepatocellular Carcinoma. The drugs Somatostatin and lanreotide have been mentioned in the context of this disorder. Affiliated tissues include liver, lung and kidney.

Related Diseases for Gastrointestinal Neuroendocrine Tumor

Diseases in the Gastrointestinal Neuroendocrine Tumor family:

Gastrointestinal Neuroendocrine Benign Tumor

Diseases related to Gastrointestinal Neuroendocrine Tumor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 116)
# Related Disease Score Top Affiliating Genes
1 neuroendocrine tumor 30.3 CHGA SST SYP
2 carcinoid syndrome 29.6 CHGA SST SYP
3 paraganglioma 29.6 CHGA SST SYP
4 small cell carcinoma 10.1 CHGA SYP
5 ureter small cell carcinoma 10.1 CHGA SYP
6 liver leiomyosarcoma 10.1 CHGA SMUG1
7 esophageal neuroendocrine tumor 10.1 CHGA SYP
8 urinary bladder small cell neuroendocrine carcinoma 10.1 CHGA SYP
9 ovarian large-cell neuroendocrine carcinoma 10.1 CHGA SYP
10 auditory system cancer 10.1 CHGA SYP
11 acinar cell cystadenocarcinoma 10.1 CHGA SYP
12 peritoneal serous adenocarcinoma 10.1 CHGA SYP
13 primary hepatic neuroendocrine carcinoma 10.1 CHGA SYP
14 small cell carcinoma of the bladder 10.1 CHGA SYP
15 pulmonary large cell neuroendocrine carcinoma 10.1 CHGA SYP
16 large cell neuroendocrine carcinoma 10.1 CHGA SYP
17 chordoid meningioma 10.1 CHGA SYP
18 olfactory groove meningioma 10.1 CHGA SYP
19 cauda equina neoplasm 10.1 CHGA SYP
20 pancreatic serous cystadenoma 10.1 CHGA SYP
21 retroperitoneal neuroblastoma 10.1 CDKN1A SST
22 cystadenoma 10.1 CHGA SYP
23 conventional angiosarcoma 10.1 CHGA SYP
24 olfactory nerve neoplasm 10.1 CHGA SYP
25 autonomic nervous system benign neoplasm 10.1 CHGA SYP
26 pulmonary sclerosing hemangioma 10.1 CHGA SYP
27 sclerosing hemangioma 10.1 CHGA SYP
28 pineocytoma 10.1 CHGA SYP
29 gastric small cell carcinoma 10.1 CHGA SYP
30 subependymoma 10.1 CHGA SYP
31 respiratory system benign neoplasm 10.1 CHGA SYP
32 anterior cranial fossa meningioma 10.1 CHGA SYP
33 gastric squamous cell carcinoma 10.1 CHGA SYP
34 pulmonary blastoma 10.1 CHGA SYP
35 pleomorphic xanthoastrocytoma 10.1 CHGA SYP
36 partial motor epilepsy 10.1 SMUG1 SYP
37 tanycytic ependymoma 10.1 CHGA SYP
38 papillary ependymoma 10.1 CHGA SYP
39 non-functioning pancreatic endocrine tumor 10.1 CHGA SYP
40 central neurocytoma 10.1 CHGA SYP
41 cervix small cell carcinoma 10.1 CHGA SYP
42 gastrointestinal neuroendocrine benign tumor 10.1 CHGA SST
43 malignant skin fibrous histiocytoma 10.1 CHGA SMUG1
44 mediastinal cancer 10.1 SMUG1 SYP
45 cerebellar liponeurocytoma 10.1 CHGA SYP
46 somatostatinoma 10.1 CHGA SST
47 gastric neuroendocrine neoplasm 10.1 CHGA SST
48 horseshoe kidney 10.1 CHGA SYP
49 cranial nerve malignant neoplasm 10.1 CHGA SYP
50 pituitary carcinoma 10.1 CHGA SST

Graphical network of the top 20 diseases related to Gastrointestinal Neuroendocrine Tumor:



Diseases related to Gastrointestinal Neuroendocrine Tumor

Symptoms & Phenotypes for Gastrointestinal Neuroendocrine Tumor

Drugs & Therapeutics for Gastrointestinal Neuroendocrine Tumor

Drugs for Gastrointestinal Neuroendocrine Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 82)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Somatostatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 51110-01-1, 38916-34-6 53481605
2 lanreotide Approved Phase 4,Phase 2,Phase 1 108736-35-2
3
Pasireotide Approved Phase 4,Phase 1 396091-73-9 9941444
4 Hypoglycemic Agents Phase 4,Phase 2
5 Angiopeptin Phase 4,Phase 2,Phase 1
6 Hormones Phase 4,Phase 2,Phase 1
7 Hormone Antagonists Phase 4,Phase 2,Phase 1
8 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 1
9
Sirolimus Approved, Investigational Phase 3,Phase 2,Phase 1 53123-88-9 46835353 6436030 5284616
10
Everolimus Approved Phase 3,Phase 2,Phase 1 159351-69-6 6442177
11
Octreotide Approved, Investigational Phase 3,Phase 2,Phase 1 83150-76-9 383414 6400441
12
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
13
Streptozocin Approved, Investigational Phase 3 18883-66-4 29327
14
Fluorouracil Approved Phase 3,Phase 2 51-21-8 3385
15 Gastrointestinal Agents Phase 3,Phase 2,Phase 1
16 Antineoplastic Agents, Hormonal Phase 3,Phase 2,Phase 1
17 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
18 Immunologic Factors Phase 3,Phase 2,Phase 1
19 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
20 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
21 Anti-Infective Agents Phase 3,Phase 2,Phase 1
22 Antifungal Agents Phase 3,Phase 2,Phase 1
23 Pharmaceutical Solutions Phase 3
24 Antimetabolites, Antineoplastic Phase 3,Phase 2
25 Antimetabolites Phase 3,Phase 2
26
Metformin Approved Phase 2 657-24-9 14219 4091
27
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
28
Dacarbazine Approved, Investigational Phase 2 4342-03-4 5351166
29
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
30
Bevacizumab Approved, Investigational Phase 2 216974-75-3
31
Pembrolizumab Approved Phase 1, Phase 2 1374853-91-4
32
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
33
Cisplatin Approved Phase 2 15663-27-1 2767 441203 84093
34
Carboplatin Approved Phase 2 41575-94-4 10339178 38904 498142
35
Etoposide Approved Phase 2 33419-42-0 36462
36
Pancrelipase Approved, Investigational Phase 2 53608-75-6
37
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
38
Panobinostat Approved, Investigational Phase 2 404950-80-7 6918837
39
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 43805 6857599 5310940 9887054
40
leucovorin Approved Phase 2 58-05-9 6006 143
41
Irinotecan Approved, Investigational Phase 2 100286-90-6, 97682-44-5 60838
42
Lenograstim Approved, Investigational Phase 2 135968-09-1
43
Fosbretabulin Investigational Phase 2,Phase 1 222030-63-9 5351387
44 Combretastatin Investigational Phase 2 82855-09-2
45 Liver Extracts Phase 2
46 Antineoplastic Agents, Phytogenic Phase 2,Phase 1,Not Applicable
47 Antimitotic Agents Phase 2
48 tyrosine Phase 2
49 Angiogenesis Modulating Agents Phase 2,Phase 1
50 Angiogenesis Inhibitors Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 52)
# Name Status NCT ID Phase Drugs
1 Study of Lanreotide in Metastatic or Recurrent Grade I-II Hindgut NET Recruiting NCT03083210 Phase 4 Lanreotide
2 Pasireotide Treatment for Neuroendocrine Tumor Withdrawn NCT02779257 Phase 4 Pasireotide;Diazoxide
3 177Lutetium-octreotate Treatment Prediction Using Multimodality Imaging in Refractory NETs Recruiting NCT01842165 Phase 3 Intravenous injection of 177Lu-octreotate
4 Cabozantinib S-malate in Treating Patients With Neuroendocrine Tumors Previously Treated With Everolimus That Are Locally Advanced, Metastatic, or Cannot Be Removed by Surgery Recruiting NCT03375320 Phase 3 Cabozantinib S-malate
5 Efficacy and Safety of Everolimus and (STZ-5FU) Given One Upfront the Other Upon Progression in Advanced pNET Recruiting NCT02246127 Phase 3 Drug: Everolimus;STZ-5FU
6 [68 Ga]-DOTANOC PET/CT in GEP-NETs Not yet recruiting NCT02608203 Phase 2, Phase 3 [68Ga]-DOTANOC PET/CT
7 Randomized Phase III of PRRT Versus Interferon Withdrawn NCT01860742 Phase 3 Interferon alpha-2b;177Lu-DOTATATE
8 Holmium-166-radioembolization in NET After Lutetium-177-dotatate; an Efficacy Study Unknown status NCT02067988 Phase 2
9 A Pilot Study of Metformin Treatment in Patients With Well-differentiated Neuroendocrine Tumors Unknown status NCT02279758 Phase 2 Metformin
10 A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers Completed NCT02132468 Phase 2 fosbretabulin tromethamine
11 68Ga-OPS202 Study for Diagnostic Imaging of GEP NET Completed NCT02162446 Phase 1, Phase 2 satoreotide trizoxetan
12 Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization Completed NCT00434109 Phase 2 Sunitinib malate
13 Phase II Study of Everolimus Combined With Octreotide LAR to Treat Advanced GI NET Completed NCT01567488 Phase 2 Everolimus;octreotide LAR
14 Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET Completed NCT02231762 Phase 2 Lanreotide Autogel 120 mg;Temozolomide (TMZ)
15 Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer Completed NCT00454363 Phase 2 Pazopanib Hydrochloride
16 Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
17 A Study of Anlotinib in Patients With Gastroenteropancreatic Neuroendocrine Tumor G3 Recruiting NCT03457844 Phase 2 Anlotinib
18 Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors Recruiting NCT03043664 Phase 1, Phase 2 Somatuline Depot;Keytruda
19 To Evaluate the Optimal Dose of 68Ga-OPS202 as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET) Recruiting NCT03220217 Phase 2 Satoreotide trizoxetan
20 Stereotactic Body Radiation Therapy (SBRT) for Unresectable Liver Metastases Recruiting NCT02185443 Phase 2
21 TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors Recruiting NCT03079440 Phase 2 TEMCAP
22 Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-DOTATATE in Advanced Gastro-entero Pancreatic Neuroendocrine Tumors Recruiting NCT02489604 Phase 2 177Lu-DOTATATE 25.9 GBq activity;177Lu-DOTATATE 18.5 GBq activity
23 Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors Recruiting NCT03600233 Phase 2 CVM-1118
24 Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg Recruiting NCT02651987 Phase 2 Lanreotide autogel 120 mg
25 Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery Recruiting NCT02595424 Phase 2 Capecitabine;Carboplatin;Cisplatin;Etoposide;Temozolomide
26 Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres Active, not recruiting NCT02859064 Phase 2 Lanreotide
27 Study of Everolimus Treatment in Newly-diagnosed Patients With Advanced Gastrointestinal Neuroendocrine Tumors Active, not recruiting NCT01648465 Phase 2 Everolimus
28 A Feasibility Study Of NAB-Paclitaxel In Combination With Carboplatin As First Line Treatment Of Gastrointestinal Neuroendocrine Carcinomas Active, not recruiting NCT02215447 Phase 2 NAB paclitaxel;Carboplatin
29 Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors Active, not recruiting NCT01841736 Phase 2 Pazopanib Hydrochloride
30 Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors Active, not recruiting NCT02575300 Phase 2 Ibrutinib
31 A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumor Terminated NCT01994213 Phase 2 Famitinib
32 Diagnostic Accuracy of Gallium-68-DOTATATE PET/CT Compared to Indium-111-pentetreotide Scintigraphy (SPECT/CT) for Gastroenteropancreatic Neuroendocrine Tumors Terminated NCT02078843 Phase 1, Phase 2 Gallium-68-DOTATATE PET/CT (index test);Indium-111-Octreoscan (standard test)
33 Study of Panobinostat in Patients With Neuroendocrine Tumors Terminated NCT00985946 Phase 2 panobinostat (LBH589)
34 FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas Terminated NCT03042780 Phase 2 FOLFIRINOX;Granulocyte colony-stimulating factor (G-CSF)
35 Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs Completed NCT01263353 Phase 1 Pasireotide LAR followed by Pasireotide LAR + Everolimus;Everolimus followed by Pasireotide LAR + Everolimus
36 Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma Completed NCT01204476 Phase 1 Everolimus;Octreotide Acetate
37 Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Completed NCT01548482 Phase 1 Temsirolimus
38 Fosbretabulin With Everolimus in Neuroendocrine Tumors With Progression Active, not recruiting NCT03014297 Phase 1 everolimus;fosbretabulin
39 Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors Unknown status NCT00454376
40 Quality-Of-Life QLQ-GINET21 Questionnaire In The Treatment Of Patients With Gastrointestinal Neuroendocrine Tumours Completed NCT02853422
41 TEP With 68-DOTANOC in Gastroenteropancreatic Neuroendocrine Tumors Completed NCT01747096 Not Applicable 68-Ga-DOTANOC
42 Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Completed NCT03017690
43 Quality of Life, Treatment Experience and Cost of Treatment With Somatostatin Analogues in Patients With Gastroenteropancreatic Neuroendocrine Tumours Completed NCT02788565
44 A Biological Study of Resveratrol's Effects on Notch-1 Signaling in Subjects With Low Grade Gastrointestinal Tumors Completed NCT01476592 Not Applicable
45 Post-Authorization Long-Term Safety Study of LUTATHERA Recruiting NCT03691064 LUTATHERA
46 Study For Evaluating The Value Of A Multi Biomarker Approach In Metastatic GEP NETs Recruiting NCT02630654
47 Clinical Utility Assay as a Biomarker for Gastroenteropancreatic and Lung Neuroendocrine Tumors Recruiting NCT02948946
48 SwissNET - a Registry for Neuroendocrine Tumours in Switzerland Recruiting NCT01039922
49 Everolimus TDM to Predict Long Term Toxicity Recruiting NCT03033186
50 Community-based Neuroendocrine Tumor (NET) Research Study Active, not recruiting NCT02730104

Search NIH Clinical Center for Gastrointestinal Neuroendocrine Tumor

Genetic Tests for Gastrointestinal Neuroendocrine Tumor

Anatomical Context for Gastrointestinal Neuroendocrine Tumor

MalaCards organs/tissues related to Gastrointestinal Neuroendocrine Tumor:

41
Liver, Lung, Kidney, Colon, Pancreas, Thyroid, Thymus

Publications for Gastrointestinal Neuroendocrine Tumor

Articles related to Gastrointestinal Neuroendocrine Tumor:

# Title Authors Year
1
Resection of the Primary Gastrointestinal Neuroendocrine Tumor Improves Survival with or without Liver Treatment. ( 29746336 )
2018
2
Peripancreatic paraganglioma mimics pancreatic/gastrointestinal neuroendocrine tumor on fine needle aspiration: Report of two cases and review of the literature. ( 28560856 )
2017
3
Gastrointestinal neuroendocrine tumor with unresectable liver metastases: an example of multimodal therapeutic approach. ( 26256906 )
2015
4
Hepatic arterial chemoembolization using drug-eluting beads in gastrointestinal neuroendocrine tumor metastatic to the liver. ( 21431978 )
2011
5
Molecular and functional characterization of non voltage-operated Ca entry in gastrointestinal neuroendocrine tumor cells. ( 21383891 )
2010
6
Antiproliferative and proapoptotic effects of histone deacetylase inhibitors on gastrointestinal neuroendocrine tumor cells. ( 17158768 )
2006
7
Definition of the role of somatostatin receptor scintigraphy in gastrointestinal neuroendocrine tumor localization. ( 9825476 )
1997

Variations for Gastrointestinal Neuroendocrine Tumor

Expression for Gastrointestinal Neuroendocrine Tumor

Search GEO for disease gene expression data for Gastrointestinal Neuroendocrine Tumor.

Pathways for Gastrointestinal Neuroendocrine Tumor

Pathways related to Gastrointestinal Neuroendocrine Tumor according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.85 CD44 SYP
2 10.33 CD44 CDKN1A

GO Terms for Gastrointestinal Neuroendocrine Tumor

Biological processes related to Gastrointestinal Neuroendocrine Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 response to organonitrogen compound GO:0010243 8.62 CDKN1A SST

Sources for Gastrointestinal Neuroendocrine Tumor

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....